AI
| Followers | 843 |
| Posts | 122988 |
| Boards Moderated | 9 |
| Alias Born | 09/05/2002 |
Friday, March 05, 2010 8:00:17 PM
Ipilimumab MoA
This diagram from yesterday’s investor presentation elaborates on
#msg-47469758 and shows the other approaches to immuno-oncology
being employed by compounds in BMY’s pipeline. (All of these except
the CD137 antagonist came from the Medarex acquisition.)
This diagram from yesterday’s investor presentation elaborates on
#msg-47469758 and shows the other approaches to immuno-oncology
being employed by compounds in BMY’s pipeline. (All of these except
the CD137 antagonist came from the Medarex acquisition.)
Discover What Traders Are Watching
Explore small cap ideas before they hit the headlines.
